TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a randomized trial of 36 people with mild to moderate multiple sclerosis, a regimen combining intravenous and oral N-acetylcysteine was associated with changes in brain connectivity and glucose metabolism after about four months. Participants receiving NAC also reported improvements in several symptoms, but the small study does not establish that NAC causes lasting clinical benefit or should be used as an MS treatment.
A randomized trial involving 36 people with mild to moderate multiple sclerosis found that participants given the antioxidant N-acetylcysteine (NAC) had changes in brain connectivity and glucose metabolism on imaging, alongside self-reported improvements in several symptoms. The findings, reported at an American Society of Functional Neuroradiology meeting and published in IBRO Neuroscience Reports, are preliminary and do not establish NAC as an effective MS treatment.
Researchers assigned 18 participants to NAC plus standard care and 18 to standard care alone. The NAC regimen combined a weekly intravenous dose of 50 milligrams per kilogram with 500 milligrams taken orally twice a day on the other six days of each week. Participants in both groups underwent assessment at the start and again after approximately four months; the follow-up timing could vary by two months.
Using an integrated PET-MRI platform, the team measured resting-state brain activity with blood oxygen level-dependent functional MRI and glucose use with fluorodeoxyglucose PET. The NAC group showed connectivity changes in the inferior frontal region, cerebellum, and parts of the temporal and parietal lobes compared with the control group. PET scans showed corresponding increases in glucose metabolism in several areas, including the inferior frontal and inferior temporal gyri.
Only the NAC group reported statistically significant improvements from baseline in the symptom questionnaires described in the report: pain, fatigue, cognition, and attention. The reported P values were 0.015, 0.016, 0.036, and 0.010, respectively. The researchers also said self-reported cognitive and attention improvements correlated with imaging changes. These results describe reported associations in a small study; the imaging findings do not by themselves show that NAC improved everyday functioning or altered the course of MS.
Testing NAC Beyond Inflammation
The study examines whether an antioxidant approach might complement existing MS care. NAC is intended to increase glutathione, a molecule involved in the body’s antioxidant defenses. The researchers framed oxidative stress as a possible contributor to brain changes in MS, alongside inflammation, and said most approved MS therapies primarily target inflammation. This trial offers early imaging data on that proposed approach, not evidence that NAC can replace established treatment.
The combination of functional MRI, PET imaging and symptom questionnaires gives researchers several ways to examine possible effects in the same participants. If larger controlled studies reproduce the findings, they could help clarify whether changes in brain activity and metabolism correspond to meaningful, durable clinical benefits. For now, the study’s size and short follow-up limit what patients and clinicians can conclude from it.
N-acetylcysteine supplement for MS
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Trial Was Conducted
The report was presented by Sahar Darabi Monadi, MD, of Thomas Jefferson University, at the American Society of Functional Neuroradiology meeting in Newport Beach, California. The study was also published in IBRO Neuroscience Reports. Its stated aim was to assess oxidative stress in MS after NAC treatment, using brain imaging and clinical symptom questionnaires.
Co-author Andrew Newberg, MD, said the team chose intravenous and oral NAC because prior data suggested oral absorption could vary. NAC has also been studied in other neurological conditions, according to the report, but results from those studies do not establish effectiveness for MS. The current trial compared the combined NAC regimen plus standard care with standard care alone; it did not test whether either route of NAC was effective on its own.
““The imaging findings seemed to correspond to some of the clinical improvements people were reporting.””
— Andrew Newberg, MD, Thomas Jefferson University
brain health supplements for multiple sclerosis
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Early Findings
The trial included just 36 participants, and the reported follow-up was around four months. The source material does not provide enough detail to assess the durability of the reported symptom changes, whether imaging differences persisted, or whether the results would apply to people with other forms or levels of MS severity. It also does not establish that NAC caused the reported improvements.
The study tested a combined intravenous and oral regimen, so it cannot show which route, dose, or treatment schedule accounted for the findings. The report does not establish long-term safety or efficacy for this use, nor does it show that NAC changes disease progression, prevents disability, or should be added to an individual’s treatment plan. Larger studies and more detailed trial data would be needed to resolve those questions.
antioxidant supplements for cognitive support
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Trials Must Test Dose and Duration
Newberg said the researchers hope the results will lead to more detailed studies of NAC dosing, treatment duration and timing. Future research would need to test the findings in larger groups, follow participants for longer, and determine whether measured brain changes track with sustained improvements in symptoms or daily function. The supplied report does not specify a date for a next trial or say whether one has begun.
Until additional evidence is available, the results should be treated as an early research finding rather than a treatment recommendation. People with MS should discuss treatment decisions with their qualified health professionals and should not change prescribed care on the basis of this study alone.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study find?
In a randomized trial of 36 people with mild to moderate MS, the group receiving NAC plus standard care showed changes in brain connectivity and glucose metabolism. Participants in that group also reported improvements in pain, fatigue, cognition and attention after treatment. The small study does not establish that NAC caused lasting benefits.
What is N-acetylcysteine?
N-acetylcysteine, or NAC, is an antioxidant-related compound that the researchers said can increase glutathione. In this trial, participants received it through both weekly intravenous infusions and oral doses. The study tested that specific combined regimen.
Does this show NAC treats multiple sclerosis?
No. The findings are preliminary and come from a small trial with follow-up of about four months. The report does not establish that NAC changes the course of MS, prevents disability or should be used as a treatment.
What research is needed next?
Further studies would need to include more participants and longer follow-up, and clarify dose, route, duration and timing. Researchers would also need to test whether imaging changes correspond to sustained benefits in symptoms or daily functioning.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
